WO2009030952A3 - Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway - Google Patents

Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway Download PDF

Info

Publication number
WO2009030952A3
WO2009030952A3 PCT/GB2008/050782 GB2008050782W WO2009030952A3 WO 2009030952 A3 WO2009030952 A3 WO 2009030952A3 GB 2008050782 W GB2008050782 W GB 2008050782W WO 2009030952 A3 WO2009030952 A3 WO 2009030952A3
Authority
WO
WIPO (PCT)
Prior art keywords
hedgehog pathway
compounds
phenylcarboxamide
effectors
inhibitors
Prior art date
Application number
PCT/GB2008/050782
Other languages
French (fr)
Other versions
WO2009030952A2 (en
Inventor
Benjamin Fauber
Alexander Hird
James Janetka
Daniel John Russell
Bin Yang
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Benjamin Fauber
Alexander Hird
James Janetka
Daniel John Russell
Bin Yang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd, Benjamin Fauber, Alexander Hird, James Janetka, Daniel John Russell, Bin Yang filed Critical Astrazeneca Ab
Publication of WO2009030952A2 publication Critical patent/WO2009030952A2/en
Publication of WO2009030952A3 publication Critical patent/WO2009030952A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present disclosure relates to heterocyclic amide compounds, which are useful for inhibiting the Hedgehog pathway, and their use in treating a disease or medical condition mediated alone or in part by Hedgehog pathway inhibition. Also disclosed are methods for manufacture of these compounds, pharmaceutical compositions including these compounds, and use of these compounds in the manufacture of medicaments for treating such diseases and medical conditions in a subject. (I)
PCT/GB2008/050782 2007-09-05 2008-09-04 Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway WO2009030952A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97010707P 2007-09-05 2007-09-05
US60/970,107 2007-09-05
US3666108P 2008-03-14 2008-03-14
US61/036,661 2008-03-14

Publications (2)

Publication Number Publication Date
WO2009030952A2 WO2009030952A2 (en) 2009-03-12
WO2009030952A3 true WO2009030952A3 (en) 2009-05-07

Family

ID=39938463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/050782 WO2009030952A2 (en) 2007-09-05 2008-09-04 Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway

Country Status (5)

Country Link
AR (1) AR068376A1 (en)
PE (1) PE20091092A1 (en)
TW (1) TW200916458A (en)
UY (1) UY31322A1 (en)
WO (1) WO2009030952A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107281214A (en) * 2017-06-06 2017-10-24 北京工业大学 Hydrogen molecule liquid/gas is preparing the application in suppressing tumor stem cell medicine
CN109369634B (en) * 2018-12-19 2021-07-27 陕西国际商贸学院 Preparation method and application of 2-methoxynicotinamide derivative with antitumor activity

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102573473B (en) * 2009-06-09 2015-05-27 加利福尼亚资本权益有限责任公司 Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of HEDGEHOG signaling
AU2011204370B2 (en) * 2010-01-07 2015-03-05 Selexagen Therapeutics, Inc. Hedgehog inhibitors
WO2011095807A1 (en) * 2010-02-07 2011-08-11 Astrazeneca Ab Combinations of mek and hh inhibitors
CN101993415B (en) * 2010-09-15 2013-08-14 北京韩美药品有限公司 Compound as Hedgehog path inhibitor, medicine composition containing same and application thereof
CN103570625A (en) 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-aryl-heteroaryl)-4-aryl-aryl carboxamide and analog as hedgehog pathway inhibitors and application thereof
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (en) 2014-09-12 2016-04-29 Novartis Ag COMPOUNDS AND COMPOSITIONS AS QUINASA INHIBITORS
US20190255042A1 (en) * 2016-11-04 2019-08-22 Impact Therapeutics, Inc Application of hedgehog pathway inhibitor in treating fibrosis diseases

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068747A1 (en) * 2002-02-12 2003-08-21 Smithkline Beecham Corporation Nicotinamide derivates useful as p38 inhibitors
WO2003088970A2 (en) * 2002-04-22 2003-10-30 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
WO2006028958A2 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
WO2006050506A1 (en) * 2004-11-03 2006-05-11 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
WO2006078283A2 (en) * 2004-04-30 2006-07-27 Genentech, Inc. Quinoxaline inhibitors of hedgehog signalling
WO2007042816A1 (en) * 2005-10-12 2007-04-19 Biolipox Ab Benzoxazoles useful in the treatment of inflammation
WO2008014291A2 (en) * 2006-07-25 2008-01-31 Irm Llc Compounds and compositions as hedgehog signaling pathway modulators

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068747A1 (en) * 2002-02-12 2003-08-21 Smithkline Beecham Corporation Nicotinamide derivates useful as p38 inhibitors
WO2003088970A2 (en) * 2002-04-22 2003-10-30 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
WO2006078283A2 (en) * 2004-04-30 2006-07-27 Genentech, Inc. Quinoxaline inhibitors of hedgehog signalling
WO2006028958A2 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
WO2006050506A1 (en) * 2004-11-03 2006-05-11 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
WO2007042816A1 (en) * 2005-10-12 2007-04-19 Biolipox Ab Benzoxazoles useful in the treatment of inflammation
WO2008014291A2 (en) * 2006-07-25 2008-01-31 Irm Llc Compounds and compositions as hedgehog signaling pathway modulators

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107281214A (en) * 2017-06-06 2017-10-24 北京工业大学 Hydrogen molecule liquid/gas is preparing the application in suppressing tumor stem cell medicine
CN109369634B (en) * 2018-12-19 2021-07-27 陕西国际商贸学院 Preparation method and application of 2-methoxynicotinamide derivative with antitumor activity

Also Published As

Publication number Publication date
TW200916458A (en) 2009-04-16
PE20091092A1 (en) 2009-08-27
AR068376A1 (en) 2009-11-11
WO2009030952A2 (en) 2009-03-12
UY31322A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
WO2009030952A3 (en) Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
EA201000365A1 (en) HETEROCYCLIC AMIDES SUITABLE FOR THE TREATMENT OF MALIGNANT NORMAL FORMATION AND PSORIASIS
WO2009155121A3 (en) Inhibitors of pi3 kinase
WO2010032875A3 (en) Heterocyclic carboxamide compounds
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
WO2010009139A3 (en) Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors
WO2010001169A3 (en) Chemical compounds 251
IL203448A (en) Azabiphenylaminobenzoic acid derivatives for use in the treatment or prevention of a pathological condition or disease susceptible to amelioration by inhibition of dhodh and pharmaceutical compositions comprising them
WO2007113558A8 (en) Quinazolinone derivatives having b-raf inhibitory activity
WO2007143600A3 (en) Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
WO2006067445A3 (en) Csf-1r kinase inhibitors
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
MX2008013212A (en) 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors.
WO2008086014A3 (en) Bis-aryl amide derivatives useful for the treatment of cancer
WO2009024611A3 (en) 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use
WO2009145456A3 (en) Heterocyclic derivatives
WO2012046030A3 (en) Phosphodiesterase inhibitors
WO2008054698A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
EP2142549A4 (en) Adenosine derivatives, method for the synthesis thereof, and the pharmaceutical compositions for the prevention and treatment of the inflammatory diseases containing the same as an active ingredient
WO2007128086A3 (en) Novel viral replication inhibitor
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
WO2007009723A3 (en) Azepane- or azocane-substituted pyrazoline derivatives, their preparation and use as medicaments
IL193252A0 (en) N-hydroxyacrylamide compounds
WO2011107608A8 (en) Heterocyclic amides as rock inhibitors
WO2009041787A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper nigrum for the prevention and treatment of inflammatory disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08788752

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08788752

Country of ref document: EP

Kind code of ref document: A2